Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Form 4 filed for Guardant Health, Inc. (GH) details a routine equity award vesting by director Steve E. Krognes on 06/30/2025. Krognes converted 154 restricted stock units (RSUs)—originally granted on 08/09/2022—into the same number of common shares at a stated price of $0, reflecting a non-cash, in-kind issuance. Following the transaction, he directly owns 17,819 common shares and retains 1,852 unvested RSUs. The RSU grant vests monthly through 06/30/2026, and no shares were sold. The filing signifies ordinary executive compensation activity with no immediate balance-sheet or cash-flow impact on the company.
Form 4 highlights for Guardant Health, Inc. (GH): Co-Chief Executive Officer and Director Helmy Eltoukhy reported two routine RSU vesting events and related tax-withholding sales over 30 June-1 July 2025.
- RSU vesting (Code “M”): 4,815 shares vested on 30 Jun 2025 and 23,997 shares vested on 1 Jul 2025, totalling 28,812 shares acquired at $0 exercise price.
- Tax withholding sales (Code “F”): 2,441 shares sold at $52.04 and 12,162 shares sold at $50.71 to cover payroll taxes, for an aggregate 14,603 shares disposed.
- Net change: Insider’s direct common-stock position rose by 14,209 shares, bringing total direct ownership to 2,423,499 shares. He also continues to hold 143,983 unvested RSUs.
- Derivative section clarifies the vesting schedules: a 4-installment 2025 grant and a previously granted award that vests quarterly over 24 months.
All transactions are routine equity-compensation events; no open-market purchases or discretionary sales were reported. The filing signals ongoing insider equity accumulation and substantial alignment, but does not reveal new operational or financial information about Guardant Health.
Director Tariq Musa of Guardant Health reported multiple transactions on June 18, 2025:
- Sale: Disposed of 3,213 shares of common stock at $49.47 per share, retaining 7,190 shares after the transaction
- Stock Options: Received 6,833 stock options with exercise price of $50.57, expiring June 18, 2035
- RSUs: Granted 4,203 restricted stock units
Both the stock options and RSUs vest in full on the earlier of June 18, 2026, or the date of the next annual stockholders meeting. This filing represents standard equity compensation for a board member, with a simultaneous sale of existing shares. The transaction was executed through an attorney-in-fact, John G. Saia.
Guardant Health Director Myrtle S. Potter reported multiple securities transactions on June 18, 2025:
- Disposed of 26 shares of Common Stock at $49.47 per share, retaining direct ownership of 18,154 shares
- Acquired new stock options for 6,833 shares with exercise price of $50.57, expiring June 18, 2035
- Received 4,203 Restricted Stock Units (RSUs) at $0 cost basis
Both the stock options and RSUs vest in full on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs earlier. The transactions were reported through Form 4 filing, with attorney John G. Saia signing on Potter's behalf on June 20, 2025.
Guardant Health director Roberto Mignone received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis
Both grants feature a one-year vesting schedule, becoming fully vested on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be standard director remuneration, filed as required under SEC Section 16(a) regulations. The filing was completed by John G. Saia as attorney-in-fact for Mignone on June 20, 2025.
Guardant Health Director Steve E. Krognes received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, exercisable until June 18, 2035
- Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis
Both grants feature a one-year cliff vesting schedule, maturing on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be part of standard director compensation. The filing was submitted by John Saia as attorney-in-fact for Krognes on June 20, 2025.
Guardant Health Director Meghan V. Joyce received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57, fully vesting after one year on June 18, 2026 (or next annual stockholders meeting if earlier). The options expire on June 18, 2035.
- Restricted Stock Units (RSUs): 4,203 RSUs granted at $0 exercise price, with the same one-year vesting schedule as the stock options.
This Form 4 filing, signed by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combination of options and RSUs aligns the director's interests with shareholders while providing both upside potential through options and guaranteed value through RSUs, subject to vesting requirements.
Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
- Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.
This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.
Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:
- Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- 4,203 Restricted Stock Units (RSUs) with no exercise price
Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.
Guardant Health Director Ian T. Clark reported multiple securities transactions on June 17-18, 2025:
- Disposed of 6,672 shares of common stock at an average price of $48.38 per share from the Thornton-Clark Family Trust
- Received a new stock option grant for 6,833 shares with exercise price of $50.57, vesting in full on June 18, 2025 or next annual stockholders meeting
- Granted 5,092 restricted stock units (RSUs) vesting in full on June 18, 2025 or next annual stockholders meeting
Following these transactions, Clark retains 9,851 shares indirectly through the family trust, plus the new equity awards. The stock sale was executed in multiple transactions within a $0.03 price range.